{
  "name": "Amgen",
  "slug": "amgen",
  "ticker": "AMGN",
  "fetched_at": "2026-02-07T12:27:33.877029+00:00",
  "news": [
    {
      "title": "Amgen resists FDA request to pull rare disease drug Tavneos from the market - Fierce Pharma",
      "link": "https://news.google.com/rss/articles/CBMiowFBVV95cUxQSTlDdjNlWEJBbE5UZ0Z2NnBQcTk4cXZaUTJTRTdpVGRvZ1MxbTBNUmtUclVXYkV0N2tNSTRWVzZoUTRZU1dVUk1kelNfYzdoYXVlLU5tX3NHbFlwc1hwcmR2QVJSamdNeHhxM2h0Sm1fYlFBNEhwdkdTc2xVVkdmcm9aVHBnT2lZRWpvVExHZWlWbDlJc3cyMkhRWFpDakFuak1v?oc=5",
      "summary": "<a href=\"https://news.google.com/rss/articles/CBMiowFBVV95cUxQSTlDdjNlWEJBbE5UZ0Z2NnBQcTk4cXZaUTJTRTdpVGRvZ1MxbTBNUmtUclVXYkV0N2tNSTRWVzZoUTRZU1dVUk1kelNfYzdoYXVlLU5tX3NHbFlwc1hwcmR2QVJSamdNeHhxM2h0Sm1fYlFBNEhwdkdTc2xVVkdmcm9aVHBnT2lZRWpvVExHZWlWbDlJc3cyMkhRWFpDakFuak1v?oc=5\" target=\"_blank\">Amgen resists FDA request to pull rare disease drug Tavneos from the market</a>&nbsp;&nbsp;<font color=\"#6f6f6f\">Fierce Pharma</font>",
      "published": "2026-02-04T12:55:00+00:00",
      "source": "Fierce Pharma"
    },
    {
      "title": "Earnings roundup: Amgen vs. FDA, Pfizer’s defense and Merck’s $70B-in-sales plan - BioPharma Dive",
      "link": "https://news.google.com/rss/articles/CBMilAFBVV95cUxNOXJjVlRweEFDdlFaZUtScWl2UFJkWWVHNzgzWXhkT3BPX2hjWjJqRGhpZVJuOW4tbUdoWlZWQURCcjY2ZndZakh5M2Y4eDhEVWRvb0NnaWkwV1lWbzNaNmxYNElnQXpVLW5fY0xtdXREbWhNa0JZd19JZnVBblNITzdzWnlEbUpLRTU0RkxWV0g3c0NP?oc=5",
      "summary": "<a href=\"https://news.google.com/rss/articles/CBMilAFBVV95cUxNOXJjVlRweEFDdlFaZUtScWl2UFJkWWVHNzgzWXhkT3BPX2hjWjJqRGhpZVJuOW4tbUdoWlZWQURCcjY2ZndZakh5M2Y4eDhEVWRvb0NnaWkwV1lWbzNaNmxYNElnQXpVLW5fY0xtdXREbWhNa0JZd19JZnVBblNITzdzWnlEbUpLRTU0RkxWV0g3c0NP?oc=5\" target=\"_blank\">Earnings roundup: Amgen vs. FDA, Pfizer’s defense and Merck’s $70B-in-sales plan</a>&nbsp;&nbsp;<font color=\"#6f6f6f\">BioPharma Dive</font>",
      "published": "2026-02-04T14:59:19+00:00",
      "source": "BioPharma Dive"
    },
    {
      "title": "Angitia raises $130M to challenge Amgen with bone-building bispecifics - Fierce Biotech",
      "link": "https://news.google.com/rss/articles/CBMioAFBVV95cUxOcU9zYlBDZWJqTmlraDdhakJsdUJYc3J5VlAzMnhMMF9MQjZFNFhlaV9BRWZ4dkcxa3l4WFkxM1RFV1pXMTNac00wbVpnX2JXWml1blNlUWtDeHhDRTk5WjdKRlRWQ2JLUllZWmFjT1FITkxSSy1tWmtuSEZfM0Z1SlFqZDhudm9kTDBveUljWkI5SVc0LXNXd21KMlRJZDhw?oc=5",
      "summary": "<a href=\"https://news.google.com/rss/articles/CBMioAFBVV95cUxOcU9zYlBDZWJqTmlraDdhakJsdUJYc3J5VlAzMnhMMF9MQjZFNFhlaV9BRWZ4dkcxa3l4WFkxM1RFV1pXMTNac00wbVpnX2JXWml1blNlUWtDeHhDRTk5WjdKRlRWQ2JLUllZWmFjT1FITkxSSy1tWmtuSEZfM0Z1SlFqZDhudm9kTDBveUljWkI5SVc0LXNXd21KMlRJZDhw?oc=5\" target=\"_blank\">Angitia raises $130M to challenge Amgen with bone-building bispecifics</a>&nbsp;&nbsp;<font color=\"#6f6f6f\">Fierce Biotech</font>",
      "published": "2026-02-05T15:17:55+00:00",
      "source": "Fierce Biotech"
    },
    {
      "title": "Amgen Shows Market Leadership With Jump To 81 RS Rating - Investor's Business Daily",
      "link": "https://news.google.com/rss/articles/CBMioAFBVV95cUxQelFkNmpSd0RwSks5MHFEeDNXdTZkZVhQMkFFcjkyU0JBbWtOd01famNJeE54akR3bGNrSUFzY2k1cHFUUnBkMWpDNWJnTDBwWHg1SlJaRzd0Wm1UWENJM1hFaVJNTXcyTE11ajd1a21aaDQ2ZjdJNl9tT3Z2TEZiWC1mUXV2ZndTeW9xcVdzT0Z5MzhMc0doWHVrYWpYZDc0?oc=5",
      "summary": "<a href=\"https://news.google.com/rss/articles/CBMioAFBVV95cUxQelFkNmpSd0RwSks5MHFEeDNXdTZkZVhQMkFFcjkyU0JBbWtOd01famNJeE54akR3bGNrSUFzY2k1cHFUUnBkMWpDNWJnTDBwWHg1SlJaRzd0Wm1UWENJM1hFaVJNTXcyTE11ajd1a21aaDQ2ZjdJNl9tT3Z2TEZiWC1mUXV2ZndTeW9xcVdzT0Z5MzhMc0doWHVrYWpYZDc0?oc=5\" target=\"_blank\">Amgen Shows Market Leadership With Jump To 81 RS Rating</a>&nbsp;&nbsp;<font color=\"#6f6f6f\">Investor's Business Daily</font>",
      "published": "2026-02-05T08:00:00+00:00",
      "source": "Investor's Business Daily"
    },
    {
      "title": "Amgen (AMGN) Stock Hits 52-Week Highs: Buy Signal? - Zacks Investment Research",
      "link": "https://news.google.com/rss/articles/CBMikAFBVV95cUxOTUpVZGZUUy1Zb0Z0anFta2o0QVhmRHJ1WlVjUlcwV2JJRDBCekRIdjh6WlVmYkNjNDVIRnFFMGxjVkZJTlF2OFlVM2xEVzZvUDdnaEZ1aVZ2eVA2eG1jMlJsZkxuV2ptZjc2ZUYyeWg2MFZ5cVR4Zi0wdnpDNTU5S21ZQ0I0d1FuR0Q1d1ZnLXo?oc=5",
      "summary": "<a href=\"https://news.google.com/rss/articles/CBMikAFBVV95cUxOTUpVZGZUUy1Zb0Z0anFta2o0QVhmRHJ1WlVjUlcwV2JJRDBCekRIdjh6WlVmYkNjNDVIRnFFMGxjVkZJTlF2OFlVM2xEVzZvUDdnaEZ1aVZ2eVA2eG1jMlJsZkxuV2ptZjc2ZUYyeWg2MFZ5cVR4Zi0wdnpDNTU5S21ZQ0I0d1FuR0Q1d1ZnLXo?oc=5\" target=\"_blank\">Amgen (AMGN) Stock Hits 52-Week Highs: Buy Signal?</a>&nbsp;&nbsp;<font color=\"#6f6f6f\">Zacks Investment Research</font>",
      "published": "2026-02-04T18:39:55+00:00",
      "source": "Zacks Investment Research"
    },
    {
      "title": "Amgen Advances Xaluritamig Into Early-Stage Trial for Hard-to-Treat Ewing Sarcoma - TipRanks",
      "link": "https://news.google.com/rss/articles/CBMizgFBVV95cUxOd3JlY2tiTWU4ZDEwV1lYbGg4ejJOd0Fsd0FSMHZZN216OVA3NE41QnRYVlk5bm9FMWxTSVNueks5T291aGY0d2lQaUdfeE8zbnZBUFAxUnFlem02aEFLTHM4T05FM3FTRkhSQl9FTDdDSDY2aVFTNGRvOWVhbFFwT0dQOFR0dFdQdkcyXzVKSGNvZ3BISUlIVkxRRVJsN2lfcGsyU1N3d21PZFZ2UWhVdkVPSng4eTlzOUxWcE1QY0NQeXJZT19peXA3SEo0UQ?oc=5",
      "summary": "<a href=\"https://news.google.com/rss/articles/CBMizgFBVV95cUxOd3JlY2tiTWU4ZDEwV1lYbGg4ejJOd0Fsd0FSMHZZN216OVA3NE41QnRYVlk5bm9FMWxTSVNueks5T291aGY0d2lQaUdfeE8zbnZBUFAxUnFlem02aEFLTHM4T05FM3FTRkhSQl9FTDdDSDY2aVFTNGRvOWVhbFFwT0dQOFR0dFdQdkcyXzVKSGNvZ3BISUlIVkxRRVJsN2lfcGsyU1N3d21PZFZ2UWhVdkVPSng4eTlzOUxWcE1QY0NQeXJZT19peXA3SEo0UQ?oc=5\" target=\"_blank\">Amgen Advances Xaluritamig Into Early-Stage Trial for Hard-to-Treat Ewing Sarcoma</a>&nbsp;&nbsp;<font color=\"#6f6f6f\">TipRanks</font>",
      "published": "2026-02-06T16:36:15+00:00",
      "source": "TipRanks"
    },
    {
      "title": "FDA Wants Drug Pulled From Market, Citing Liver Risk. Company Says No. - MedPage Today",
      "link": "https://news.google.com/rss/articles/CBMid0FVX3lxTE9UTUJYME54aGNQdVc4b0FzdWRaTjJXbWNZZ05veU9lRGFuVWtBLXZyc0JTaldSYUk5aDRId1U5T1owWVlkMWR2a1N6UE02RjhxSE5NNWhLZUJYRmlOVkxIWHgtUmhENnVZR2I5VVZCMXJDWk1lTDRr?oc=5",
      "summary": "<a href=\"https://news.google.com/rss/articles/CBMid0FVX3lxTE9UTUJYME54aGNQdVc4b0FzdWRaTjJXbWNZZ05veU9lRGFuVWtBLXZyc0JTaldSYUk5aDRId1U5T1owWVlkMWR2a1N6UE02RjhxSE5NNWhLZUJYRmlOVkxIWHgtUmhENnVZR2I5VVZCMXJDWk1lTDRr?oc=5\" target=\"_blank\">FDA Wants Drug Pulled From Market, Citing Liver Risk. Company Says No.</a>&nbsp;&nbsp;<font color=\"#6f6f6f\">MedPage Today</font>",
      "published": "2026-02-04T21:31:04+00:00",
      "source": "MedPage Today"
    },
    {
      "title": "Amgen Will Not Heed FDA Request To Withdraw Rare Disease Drug Tavneos - BioSpace",
      "link": "https://news.google.com/rss/articles/CBMinwFBVV95cUxNellYR1ZjTzZWVE9JZGhjTnJ2UGhTYjZKdlY0Z1I5MG1QNlF1SzFNbHI3WmpkWkpBbVQyTXc4NmxvR1Nac2pkbk1LdWZlSnAxRjBrUGZJWWtQS3l6UjJGUUIxblM5d0pXdW85MVdtU3gyUklMS21faDlZZ3ZLbnVFZHc2eDVDTEJwTUVlOHItdnNURm9odDlITWFWVHI1Y2s?oc=5",
      "summary": "<a href=\"https://news.google.com/rss/articles/CBMinwFBVV95cUxNellYR1ZjTzZWVE9JZGhjTnJ2UGhTYjZKdlY0Z1I5MG1QNlF1SzFNbHI3WmpkWkpBbVQyTXc4NmxvR1Nac2pkbk1LdWZlSnAxRjBrUGZJWWtQS3l6UjJGUUIxblM5d0pXdW85MVdtU3gyUklMS21faDlZZ3ZLbnVFZHc2eDVDTEJwTUVlOHItdnNURm9odDlITWFWVHI1Y2s?oc=5\" target=\"_blank\">Amgen Will Not Heed FDA Request To Withdraw Rare Disease Drug Tavneos</a>&nbsp;&nbsp;<font color=\"#6f6f6f\">BioSpace</font>",
      "published": "2026-02-04T13:51:15+00:00",
      "source": "BioSpace"
    }
  ],
  "product_launches": [
    {
      "title": "Amgen: Solid New-Product Uptake Offset by Legacy Erosion and Execution Risks, Warranting a Hold Rating - TipRanks",
      "link": "https://news.google.com/rss/articles/CBMi3wFBVV95cUxNOGRMMXF5YlJsZk83RlJqN3ozY1VjSUlkYnpXX05zZmZCWnRoRHNrTk9IdGVYczVZVk9WTkw0MjNKYmkySWZXOUdDdGFXZWRrRjR6U0VSbmtJbkx6NkQ1bkQycGxEWDlZRVdSTzJidFBabTZLOWxkWnI0WktQMXRNX1lCS04xMmFhV3lrV1BDbGRmRlVhSnBfV1BaMmoyc3hTV3lZOTBRX08tRnRuX0hKTkplc05sN1Q2enYxSDE4X2ZkcFVVU1lENks1VUJHWFZzY2tfOUIxaFBEa1dnRkQw?oc=5",
      "summary": "<a href=\"https://news.google.com/rss/articles/CBMi3wFBVV95cUxNOGRMMXF5YlJsZk83RlJqN3ozY1VjSUlkYnpXX05zZmZCWnRoRHNrTk9IdGVYczVZVk9WTkw0MjNKYmkySWZXOUdDdGFXZWRrRjR6U0VSbmtJbkx6NkQ1bkQycGxEWDlZRVdSTzJidFBabTZLOWxkWnI0WktQMXRNX1lCS04xMmFhV3lrV1BDbGRmRlVhSnBfV1BaMmoyc3hTV3lZOTBRX08tRnRuX0hKTkplc05sN1Q2enYxSDE4X2ZkcFVVU1lENks1VUJHWFZzY2tfOUIxaFBEa1dnRkQw?oc=5\" target=\"_blank\">Amgen: Solid New-Product Uptake Offset by Legacy Erosion and Execution Risks, Warranting a Hold Rating</a>&nbsp;&nbsp;<font color=\"#6f6f6f\">TipRanks</font>",
      "published": "2026-02-04T03:18:16+00:00",
      "source": "TipRanks"
    },
    {
      "title": "Amgen, Kyowa Kirin Bolster Safety Profile for Atopic Dermatitis Hopeful - BioSpace",
      "link": "https://news.google.com/rss/articles/CBMisgFBVV95cUxQVEJYNkQ0cURCVTNSd1VIbU1JLWtmblBqXzNDZnp6SVBBcWpGcm5zNWdaUFZwdjN4aGR4TnJoYm9PMWk2STRNdmdKMjRKU2pQVURtamRpUDBja3ZhYk1ONHJRemdtdkpVRHJ3SXBESkdyNG1hMW1ZQW4wb0xpYmMxY0E5RkRyVERkaS1FczJlUmZmbVZRN2VWenB5czdkeFg4eG5jNkZqQm9RU3FaMjl6dl9R?oc=5",
      "summary": "<a href=\"https://news.google.com/rss/articles/CBMisgFBVV95cUxQVEJYNkQ0cURCVTNSd1VIbU1JLWtmblBqXzNDZnp6SVBBcWpGcm5zNWdaUFZwdjN4aGR4TnJoYm9PMWk2STRNdmdKMjRKU2pQVURtamRpUDBja3ZhYk1ONHJRemdtdkpVRHJ3SXBESkdyNG1hMW1ZQW4wb0xpYmMxY0E5RkRyVERkaS1FczJlUmZmbVZRN2VWenB5czdkeFg4eG5jNkZqQm9RU3FaMjl6dl9R?oc=5\" target=\"_blank\">Amgen, Kyowa Kirin Bolster Safety Profile for Atopic Dermatitis Hopeful</a>&nbsp;&nbsp;<font color=\"#6f6f6f\">BioSpace</font>",
      "published": "2025-09-10T07:00:00+00:00",
      "source": "BioSpace"
    },
    {
      "title": "A Look at Amgen’s (AMGN) Valuation as Repatha Scores Major Trial Win and Direct Sales Launch Spurs Optimism - Yahoo Finance",
      "link": "https://news.google.com/rss/articles/CBMihgFBVV95cUxObWpGcHFxUm1WbnhhdFJUOW1kcjlGamhOQTdxdnVqWVRmQkxzNzdYd0poQk96QVByUENRMHhxQlFhVXctWGhjSWw4bjIzMXoxdFhLaVhpU0xMbnltTjhBejY4X1lQOWJuRENDNjVTbWxRRjZMMERRT0RVLVdETjhUcVljeTM3QQ?oc=5",
      "summary": "<a href=\"https://news.google.com/rss/articles/CBMihgFBVV95cUxObWpGcHFxUm1WbnhhdFJUOW1kcjlGamhOQTdxdnVqWVRmQkxzNzdYd0poQk96QVByUENRMHhxQlFhVXctWGhjSWw4bjIzMXoxdFhLaVhpU0xMbnltTjhBejY4X1lQOWJuRENDNjVTbWxRRjZMMERRT0RVLVdETjhUcVljeTM3QQ?oc=5\" target=\"_blank\">A Look at Amgen’s (AMGN) Valuation as Repatha Scores Major Trial Win and Direct Sales Launch Spurs Optimism</a>&nbsp;&nbsp;<font color=\"#6f6f6f\">Yahoo Finance</font>",
      "published": "2025-10-16T07:00:00+00:00",
      "source": "Yahoo Finance"
    },
    {
      "title": "A Look at Amgen’s (AMGN) Valuation Following FDA Nod Expanding Repatha’s Patient Reach - simplywall.st",
      "link": "https://news.google.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?oc=5",
      "summary": "<a href=\"https://news.google.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?oc=5\" target=\"_blank\">A Look at Amgen’s (AMGN) Valuation Following FDA Nod Expanding Repatha’s Patient Reach</a>&nbsp;&nbsp;<font color=\"#6f6f6f\">simplywall.st</font>",
      "published": "2025-09-08T07:00:00+00:00",
      "source": "simplywall.st"
    },
    {
      "title": "3 major patent losses this year — and a key strategy to fill the gaps - Pharma Voice",
      "link": "https://news.google.com/rss/articles/CBMimgFBVV95cUxPNGpDZTgwdDRLOFozTU9HVGVzWWpkS1dXSEd4X1c0RzVVdktmbzUwVVhWSW01X3BkbGl5c084anVWeHVkX1FEU1pEMm13ZW91WlBwNE5CQVVmYURaaEFOREx0dk1fTTJyT01lYW1ZVXBOV2ZXTTdFamNYc2FVbTAyazJOeEVnNkszUXphcjI5blNXSV9wZ0tmcThR?oc=5",
      "summary": "<a href=\"https://news.google.com/rss/articles/CBMimgFBVV95cUxPNGpDZTgwdDRLOFozTU9HVGVzWWpkS1dXSEd4X1c0RzVVdktmbzUwVVhWSW01X3BkbGl5c084anVWeHVkX1FEU1pEMm13ZW91WlBwNE5CQVVmYURaaEFOREx0dk1fTTJyT01lYW1ZVXBOV2ZXTTdFamNYc2FVbTAyazJOeEVnNkszUXphcjI5blNXSV9wZ0tmcThR?oc=5\" target=\"_blank\">3 major patent losses this year — and a key strategy to fill the gaps</a>&nbsp;&nbsp;<font color=\"#6f6f6f\">Pharma Voice</font>",
      "published": "2025-07-21T07:00:00+00:00",
      "source": "Pharma Voice"
    }
  ],
  "stock": {
    "ticker": "AMGN",
    "currency": "USD",
    "latest": {
      "date": "2026-02-06",
      "close": 384.32000732421875
    },
    "history": [
      {
        "date": "2026-01-29",
        "close": 342.94000244140625
      },
      {
        "date": "2026-01-30",
        "close": 341.8800048828125
      },
      {
        "date": "2026-02-02",
        "close": 344.67999267578125
      },
      {
        "date": "2026-02-03",
        "close": 338.5899963378906
      },
      {
        "date": "2026-02-04",
        "close": 366.20001220703125
      },
      {
        "date": "2026-02-05",
        "close": 367.79998779296875
      },
      {
        "date": "2026-02-06",
        "close": 384.32000732421875
      }
    ],
    "name": "Amgen Inc."
  }
}